Skip to content
Business Company News, Medical Health Aged Care

GMHBA delivers strong results and record member satisfaction in milestone year

GMHBA Limited 2 mins read

Geelong-based not-for-profit private health insurer GMHBA has released its full-year results, reporting record customer satisfaction, strong membership sales growth, improved customer loyalty and major investments in technology and health services.

More than 316,000 Australians are now covered by GMHBA Ltd, with 161,950 memberships across GMHBA and its value-driven online brand, Frank Health Insurance. Customer satisfaction remains among the highest in the industry, with scores of 9.1 out of 10 for GMHBA members and 8.4 out of 10 for Frank members.

“Our purpose has never changed, to put people before profit and deliver value and care our members and patients can rely on,” said CEO David Greig.

“As we celebrated 90 years, we reflected on our long history of caring for community and looked ahead to how we can continue to serve members in a rapidly changing healthcare environment.

“With strong results, record satisfaction, and sustainable growth, GMHBA is well positioned for the future.”

Click here to access our FY25 financial and healthcare data and results

 

 

 


About us:

About GMHBA Health Insurance

GMHBA is an Australian not for profit health insurance and care company. We have served the community since 1934, and with more than 90 years’ experience, we have become Australia’s leading regionally based not for profit private health insurer.

Through our personalised approach and exceptional customer service, we put the health and wellbeing of our members and communities first. Our approach is guided by our philosophy, Healthier Together and decisions are made with our members first and foremost in mind.


Contact details:

GMHBA Head of Corporate Communications Meg Rayner

0458 418 823 or [email protected]

For the latest announcements and updates visit GMHBA Media Centre.

Media

More from this category

  • Business Company News, General News
  • 26/03/2026
  • 08:41
UNSW Sydney

Why does panic buying spread so fast among Australians?

As fears over fuel supply ripple through Australia, UNSW Business School experts say panic buying is driven as much byinstinctand expectationsas by actual shortages. When uncertainty rises, so does the urge to act. Panic buying has re-emerged across Australia as global tensions in the Middle East raise concerns about global andfuel supplychains, leading to long queues and spikes in demand at petrol stations. While similar behaviour was seen during the COVID-19 pandemic, UNSW Business School experts say the current wave is being driven more byperceptionand expectation than actual shortages. “Anytime there is fear and uncertainty, those emotions bring out more…

  • Government Federal, Medical Health Aged Care
  • 26/03/2026
  • 06:10
Australian College of Nursing

Let nurse practitioners lead Urgent Care Clinics to address staffing issues

The Australian College of Nursing is calling on the Federal Government to revise guidelines to allow nurse practitioners to lead care independently in Medicare Urgent Care Clinics (UCCs), with GP recruitment an ongoing challenge for the program. Nurse practitioners are among the most highly qualified clinicians in our health system, capable of leading UCCs, but the current Medicare Urgent Care Clinic Program Operational Guidance mandates that clinics will be GP-led, with a vocationally registered general practitioner required at a minimum. The latest evaluation of the program noted recruitment of appropriately qualified doctors remains an issue, and that Medicare Benefits Schedule…

  • Contains:
  • Medical Health Aged Care
  • 26/03/2026
  • 06:00
Monash University

New medicine piggybacks onto fat absorption pathways to allow oral delivery and support clinical trial in major depressive disorder

Monash University and Seaport Therapeutics have developed a new approach to delivering drug molecules that piggybacks onto natural fat absorption pathways to allow oral delivery of some drugs previously requiring injection. The research, published today inScience Translational Medicine, describes the first clinical evidence that a fat, or lipid, modified version of the naturally occurring neurosteroid allopregnanolone (GlyphAllo™) can result in high enough levels of the substance in the human bloodstream to be potentially effective. The endogenous neurosteroid allopregnanolone is a well-established molecule known for its clinically validated antidepressant, anti-anxiety and sleep-promoting effects – but to this point had to be…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.